Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Ezetimibe (Zetia) vs Inclisiran (Leqvio): Ezetimibe (Zetia) has the stronger overall evidence (4.4 vs 4.1/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Ezetimibe (Zetia) wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Ezetimibe (Zetia) and Inclisiran (Leqvio) have evidence — compare verdict strength side-by-side.
10 mg once daily, with or without food, alone or added to a statin — under a clinician. A prescription drug; not a self-directed supplement regimen.
any
Oral tablet (ezetimibe 10 mg)
284 mg (300 mg inclisiran sodium) by subcutaneous injection administered by a healthcare professional on day 1, again at day 90 (month 3), then every 6 months thereafter. A prescription drug; this is the approved regimen, not a self-directed supplement protocol.
any
Prefilled subcutaneous injection (inclisiran 284 mg)
2–4 weeks
Months to years
Throughout use
Throughout use
Weeks to months; sustained
Ongoing
Outcomes trials ongoing
Around each injection
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
The New England journal of medicine (2015) · Rct · n=18144
IMPROVE-IT randomized trial: ~18,000 patients stabilized after acute coronary syndromes
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Lancet (London, England) (2011) · Rct · n=9438
SHARP randomized placebo-controlled trial in chronic kidney disease (n≈9,400)
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
The New England journal of medicine (2008) · Rct · n=1873
SEAS randomized trial in patients with mild-to-moderate aortic stenosis
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
The New England journal of medicine (2020) · Rct · n=3178
ORION-10 and ORION-11 randomized, placebo-controlled phase 3 trials in atherosclerotic cardiovascular disease / high risk
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
The New England journal of medicine (2020) · Rct · n=482
ORION-9 randomized, placebo-controlled phase 3 trial in heterozygous familial hypercholesterolemia
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
The New England journal of medicine (2017) · Rct · n=501
ORION-1 phase 2, double-blind, placebo-controlled, multiple-ascending-dose trial
Ezetimibe (Zetia) has a higher evidence score (4.4/10 vs 4.1/10) and wins in 1 of 3 categories.
For support heart health, Inclisiran (Leqvio) has a higher relevance score (70 vs 68).
No known interactions between Ezetimibe (Zetia) and Inclisiran (Leqvio) have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.